Chapter 11: Biocatalysis in Organic Chemistry

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive, the show where we slice through dense research and industrial reports to give you the absolute core knowledge you need without the headache of reading the into the microscopic world,

specifically focusing on this silent fundamental revolution that's happening in manufacturing and medicine, a field known as biocatalysis in organic chemistry.

Okay, biocatalysis.

Let's unpack that right away.

If that sounds like a super intimidating academic term, just think of this deep dive as your shortcut.

It's about understanding how microorganisms, you know, your fungi and bacteria and the enzymes they make are just completely changing how we That's it, exactly.

I mean, we're talking about drugs, food ingredients, massive commodity chemicals.

The basic idea is that in a lot of cases, nature is just a way better chemist than we are.

A cleaner one, for sure.

That's the core of it.

Our mission here is to explore these

biotransformations.

It's the process where we use these microbes and their enzymes to

interconvert all sorts of different organic compounds.

And this isn't just, you know, accidental fermentation like making beer.

Oh, no, not at all.

We're talking about

highly precise, really targeted chemical reactions.

And they're being carried out by these tiny biological machines.

And here's where it gets really fascinating.

This is the aha moment that explains why this tech is just taking over pharmaceuticals and the chemical industry.

It all comes down to geometry.

Specifically, a word called

stereospecificity.

Which is also called enantioselectivity.

Right.

And it's so important because of the shape of the catalyst itself, the enzyme, the enzyme, right?

The active site of an enzyme.

That's the tiny pocket where the reaction happens.

It's an asymmetric surface.

It's chiral.

Think of it like a glove.

Okay.

A glove.

Exactly.

So if your molecule, your substrate fits perfectly into that glove, it can only be processed in one very specific way.

And that geometry guarantees that the reaction will produce a specific three -dimensional version, a stereoisomer as the only product.

And that is the defining competitive advantage right there.

Because in standard traditional chemistry in a big vat, you often get what's called a racemic mixture.

A messy 50 -50 blend of both mirror image molecules.

So using your glove analogy, traditional chemistry gives you a big pile of left and right gloves, all mixed up.

All mixed up.

But biology, through the enzyme, it only makes the left glove or only the right one.

Never both.

And that matters so much in the body, right?

Because only one of those mirror images might work.

The left glove fits the target,

but the right one is useless.

Worse than useless sometimes.

The right glove might be inactive, but sometimes tragically, it can be actively toxic.

It can have a completely different harmful effect.

Enzymes just, they eliminate that whole problem.

You get the pure desired product right from the start.

And getting that level of precision with normal chemistry is what?

Hard.

Extremely difficult.

Sometimes it's just outright impossible.

So stereospecificity is the killer app, no question.

But for an industrial process, you need more than just accuracy.

What are the other big compelling advantages that make enzymes these sort of ultimate industrial chemists?

Well, we can really summarize them across four critical areas.

And the first one is just pure efficiency.

Efficient.

Enzymes are molecular shortcuts.

A single enzyme step can, and frequently does, replace many, many steps in a conventional chemical synthesis.

Wow.

We're talking like a dozen steps sometimes.

Sometimes even more.

And fewer steps means less equipment, less purification between steps, less complexity.

And less energy, less waste.

Which I guess brings us to the second big advantage.

The mild conditions.

Yeah.

And the contrast here is really stark.

Chemical synthesis, it often needs extreme conditions.

We're talking high heat, high pressure, sometimes really harsh toxic solvents.

Right.

Stuff you need special reactors for.

It sounds expensive.

It is.

It takes a huge amount of energy.

But enzymes, they evolved inside living cells.

So they work perfectly at ambient temperature, normal atmospheric pressure.

And usually in simple water -based solutions, the energy savings are just staggering.

So we save money.

We go green.

And you also get a much higher level of purity, which is a massive concern, especially in pharma.

Oh, absolutely.

In chemical synthesis, you're constantly fighting against side reactions.

Things like isomerization, racemization, epimerization, all these unwanted rearrangements.

Things that can ruin your final product.

Exactly.

Especially if your target molecule is fragile or labile, as we say.

Yeah.

These side reactions can just destroy your yield and force you into these really intense purification steps.

But enzymes, they are so specific.

They're tailored for one job and one job only.

So they generally avoid all that mess.

The product is cleaner from the moment it's made.

And the final piece of the puzzle has to be the speed of the reaction.

Yeah.

Enzymes are accelerators.

The ultimate accelerators.

I mean, the kind of spade we're talking about is almost hard to comprehend.

Give us some numbers.

They accelerate reaction rates by factors of 10 to the 8 up to 10 to the 14.

That's 100 million to 100 trillion times faster.

So that's taking a reaction that might take a century and making it happen in a second.

Literally.

So for all these reasons, the speed, the mild conditions, the purity, the efficiency, and especially that stereo specificity of biotransformations are just incredibly valuable.

And often they're indisputable.

Okay.

So since specificity is the bedrock of this whole field,

we should probably take a quick detour and just define the language.

For anyone listening who maybe doesn't have a deep organic chemistry background, understanding this molecular geometry is going to be essential for the case studies we're about to get into.

It is.

Let's start with the absolute fundamental concept, which is stereochemistry.

The most basic term is enantiomer.

Enantiomer.

These are simply compounds that are non -superimposable mirror images of each other.

The classic example is your hands.

Your left hand and your right hand are mirror images, but you can't stack them perfectly on top of each other.

And you can't fit your right hand into a left -hand glove.

Got it.

Exactly.

And when you shine plain polarized light through a solution of these molecules, they rotate that plane of light.

If they do, we call them optically active compounds.

And the reason they're optically active is because the molecule itself lacks a certain kind of symmetry, right?

Correct.

It lacks a plane or a center of symmetry.

And the part of the molecule that usually creates this asymmetry is called a chiral center.

Okay.

So what is a chiral center?

Most of the time in biology, it's an asymmetric carbon atom.

This is a carbon that's bonded to four completely different groups.

And because those four groups are different, the arrangement in 3D space can be configured in two distinct non -superimposable ways.

The two mirror images.

The two mirror images.

Now there's also a related term, prochiral center.

That sounds like it's almost chiral.

That's a great way to think about it.

A procural center is a carbon that currently has two identical groups attached, so it's not yet optically active.

But it's only one reaction away.

If you replace just one of those identical groups with something else, boom, it instantly becomes a chiral center.

Okay.

So once we know a molecule is chiral, we need a way to label which mirror image we're talking about.

That's the RS convention, I believe.

Yes, exactly.

This gives us the absolute molecular asymmetry.

The convention uses R for rectus, which is Latin for right or clockwise, and S for sinister, which is Latin for left or counterclockwise.

And this is all based on a set of priority rules.

Right.

We assign a priority to the four groups attached to that chiral carbon.

Priority one goes to the group with the atom that has the highest atomic number.

If there's a tie, you move to the next atom out.

And then you orient the molecule in a specific way.

You do.

You point the lowest priority group away from you, into the page, so to speak.

Then you just look at the remaining three groups.

If you count from priority one to two to three, and your eye moves in a clockwise direction, it's R.

And if it's counterclockwise, it's S.

It's S.

It's a universal system, so chemists everywhere know exactly which 3D shape they're dealing with.

Perfect.

And understanding that language leads us right into how we measure the selectivity in the lab.

How does an industrial chemist actually quantify how successful a reaction was?

How pure is my final product?

We use two key parameters.

The first is enantiomeric excess, or just E.

This is a simple measure of the purity of your product.

You take the concentration of the major enantiomer, subtract the minor one, and divide by the total.

So if I have a 50 -50 mix, a racemic mixture, my E is zero?

Zero.

If you have a perfectly pure product, 100 % of the R version and 0 % of the S, your E is one, or 100%.

Okay, so E measures the product.

What measures the enzyme itself?

For that, we use the enantiomeric ratio, or the E value.

This is a score that describes the enzyme's stereoselectivity.

It tells you how good the enzyme is at telling the two mirror images apart.

So what's a good E value?

What's the score you're aiming for in an industry?

For any kind of acceptable resolution, especially in pharmaceuticals where purity is everything, you need an E value above 20.

That's the benchmark.

If your enzyme has an E of,

say, five, it's basically useless for that process.

Good to know.

Now, even with all these amazing advantages, enzymes aren't perfect out of the box.

You mentioned scientists have had to overcome some pretty big hurdles to make this all work on an industrial scale.

What were the main limitations?

The initial problems were definitely showstoppers.

They fall into about three categories.

First is stability and solvents.

Right, enzymes evolved to work in water.

Exactly.

So most of them have very low activity or none at all in the kind of anhydrous organic solvents you need to dissolve your starting materials.

And on top of that, they're proteins.

They unfold and become inactive.

They denature if you heat them up too much or swing the pH around.

So how did industry get around that?

You can't just run every reaction of water.

We use a couple of clever tricks.

One is immobilizing the enzymes.

We basically glue them onto a solid support, like a little plastic bead or a membrane.

This makes them way more stable and lets you pack them into a column for continuous flow reactions.

The other method is using two -phase solvent systems.

You have your enzyme happy in a tiny little bit of water and that's sitting in a much larger volume of an organic solvent that doesn't mix with water.

The reactants and products are in the organic phase, so you get the best of both worlds.

Smart.

What was the second major hurdle?

You mentioned inhibition.

Right.

Enzymes often suffer from substrate and product inhibition.

If you dump in too much starting material, the substrate, or if the product builds up too much, the enzyme just grinds to a halt.

Which is a huge problem for mass production.

You want high concentrations.

You do.

So the solution is some really sophisticated engineering.

Instead of just dumping everything in a batch, you use systems that continuously feed in the substrate at a low controlled rate, while at the same time you're continuously removing the product.

This keeps the enzyme in its happy place working at top speed.

And the final issue is always cost, right?

Enzymes and their cofactors can be expensive.

That's a big one.

Some enzymes need these complex helper molecules or cofactors to work.

And if you have to add an equal amount of an expensive cofactor for every bit of product you make, your process is dead in the water financially.

So that's the fix.

The solution was a huge win for biochemical engineering.

Developing systems to regenerate cofactors right there in the reactor.

So instead of adding a huge amount, you add a tiny catalytic amount and a second enzyme system just recycles it over and over.

That was the breakthrough that made many of these processes economically viable.

That sets the stage beautifully.

So let's move from the theory to a really concrete,

high impact historical example.

One that shows the power of biocatalysis in action.

The microbial transformation of steroids,

specifically making cortisone.

Yes, this is a foundational case study.

It goes all the way back to the 1950s.

And it was one of the earliest huge industrial successes.

It just dramatically showed how enzymes could do reactions with incredible regioselectivity.

Meaning they attack one specific position on a really complex molecule.

Exactly.

And with stereospecificity at these unactivated carbon centers where traditional chemists just really, really struggled.

And to really appreciate that struggle, you have to picture the steroid molecule.

It's not a simple thing.

Not at all.

The steroid nucleus has four fused carbon rings labeled A, B, C, and D.

And it's not flat.

It's a big, bulky, three -dimensional structure.

The exact position and orientation of every little group attached to it determines what it does biologically.

And there are a ton of places a reaction could happen.

Oh, yes.

You have 18 secondary carbon atoms just within the ring system.

And an enzyme that adds a hydroxyl group, a hydroxylase, is named for the specific carbon it attacks.

A 21 -hydroxylase, for example.

And at those secondary positions, the group can be attached in two different ways, right?

The alpha and beta configurations?

Correct.

The alpha configuration is below the plane of the ring.

And the beta configuration is above it.

So that gives you 36 possible hydroxylation sites just based on position and stereochemistry.

And this is where the power of microbial diversity comes in.

It's incredible.

For every single one of those 18 secondary carbons in either the alpha or the beta configuration,

we have found a different specific microbial hydroxylase that can do that one specific job.

Nature has a tool for everything.

So let's apply that precision to the story of cortisone production, which really put biocatalysis on the map.

This was a huge drug discovery.

A massive one.

Cortisone is a steroid made by the adrenal gland, and its profound anti -inflammatory effects were discovered in 1949.

The medical demand was just enormous overnight.

But production was a huge problem.

Because the chemical synthesis was a complete nightmare.

It was nearly impossible to scale up.

The first chemical route took an incredible 31 separate steps.

It started from deoxycholic acid, which they got from beef bile.

And to give you an idea of the waste?

Yeah, hit me with the numbers.

You needed 615 kilograms of deoxycholic acid to make just one kilogram of cortisone acetate.

The price reflected that.

It was $200 per gram.

The drug was basically inaccessible to most people.

And what was the big chemical roadblock in that 31 step process?

The main problem was getting a crucial oxygen atom onto the C11 position, that C11 hydroxylation.

The chemical pathway required 9 separate really difficult steps just to do that one thing.

It was brutal.

Okay, so set the scene for the microbial breakthrough in 1952.

Researchers at Upjohn were screening hundreds and hundreds of different microbes.

And they discovered that the common bread mold, Rhizopus aresis, could perform that exact C11 hydroxylation on an intermediate called progesterone.

Just one step.

One microbial step replaced nine chemical steps.

Exactly.

And at the same time, researchers at SWIB found another mold, aspergillus niter, that could do the same thing.

What was the immediate industrial impact of that discovery?

It was absolutely revolutionary that one biotransformation shortened the entire synthesis from 31 steps down to just 11.

And the microbial step was done at 37 degrees Celsius in water.

So the energy savings were huge.

And the price of cortisone just plummeted almost overnight from $200 a gram to $6 a gram.

A 33 -fold price drop.

That completely changed who could access this drug.

But the push for lower costs didn't stop there.

They started looking for cheaper raw materials.

Right.

They moved away from expensive animal bile to cheap plant sterols.

Things like stigmastrol and cetostrol from soybean oil and diastgenin from the Mexican Barbasco plant.

Much cheaper starting points.

But the plant sterols had a different problem.

They had this long, unwanted side chain attached to the molecule.

And removing that side chain chemically was, again, difficult and expensive.

So the solution, once again, came from the microbial world.

Specifically, from a group of bacteria called mycobacteria.

And these microbes naturally eat sterols for energy.

They do.

Which means they have enzymes that are perfectly evolved to chew up those side chains.

So the trick was to harness that natural degradation pathway but stop it my way through.

Precisely.

You didn't want the mycobacteria to destroy the whole molecule.

So scientists engineered mutant strains that were genetically blocked.

They couldn't degrade the sterols past a certain desired intermediate.

So the process now used cheap starting materials and a microbe to clip the side chain off cleanly.

And that combination of cheaper materials and a better microbial process was the final nail in the coffin for the high price.

It was.

By 1980, the price of cortisone had dropped even further.

Down to 46 cents per gram.

That's a 400 -fold reduction from the original price.

It's the perfect story to show the power of biocatalysis.

Not just doing something chemically difficult, but doing it in a way that has this massive positive impact on society.

The cortisone story is incredible for showing efficiency and cost reduction.

But let's pivot now to the modern era, to the pharmaceutical and agrochemical industries, where that stereo specificity we talked about isn't just an advantage, it's a matter of life and death.

This is where chirality is absolutely paramount.

I mean, think about how a drug works.

It binds to a very specific biological target in your body, a receptor, an enzyme.

And since those targets are themselves chiral, the interaction is incredibly shape dependent.

So if you use a racemic mixture, that 50 -50 blend, you're giving the patient a drug that's at least half useless

and potentially half harmful.

That's the real danger.

The assumption that the inactive isomer is just harmless has caused major problems in the past.

Today, about a quarter of all drugs are chiral.

And regulators now basically mandate that you market the pure, homochiral drug whenever possible.

It's about safety and predictable effects.

Can you give us a couple of concrete examples?

I think those really drive the point home.

Sure.

A classic one is the anti -tuberculosis drug ethambutil.

The dextrorotatory isomer, one -mirror image, is potent and effective.

But the levirotatory isomer, its mirror image, causes optic nerve degeneration.

It leads to blindness.

Wow.

So you have to separate them.

You absolutely have to.

Another great example is propoxyphene.

One isomer is an analgesic, a pain reliever.

The other isomer is a cough suppressant.

They have completely different jobs in the body.

OK.

So the demand for producing just one mirror image, one left -hand molecule, is huge.

And this means the industry needs these things called chiral synthons, or optically active building blocks.

And biocatalysis is perfect for making them.

It is.

A great modern example is making intermediates for what are called beta -3 -3 receptor agonists.

What are those for?

These are potential new treatments for complex diseases, like type 2 diabetes and obesity.

The receptors are mainly on fat cells.

But synthesizing these complex drugs requires creating several specific chiral centers.

And biocatalysis is used for two of the crucial early steps.

So describe that first biocatalytic reaction.

The first one is an enantioselective reduction.

The starting material is a racemic ketone.

And for this, they use whole cells of a bacterium called sphingomonas pathimobolis.

This bug does a reduction reaction, turning the ketone into an alcohol.

And it's incredibly selective.

It produces the desired R alcohol with an anti -americ excess of over 98%.

Industrial -grade purity in one step, using a whole bug.

What about the second reaction?

The second involves something called an enzymatic resolution.

For this, they use wet cells of mycobacterium neoorum.

These cells have an enzyme, an amidase, that is also highly selective.

It resolves a racemic amide mixture, generating the chiral S acid that they need.

It's amazing how they stitch these different microbial specialists together to build one drug.

OK, let's look at an agrochemical example now.

S2 -chloropropionic acid.

This is an intermediate for a major class of herbicides.

That's right.

These are the aryloxyphenoxypropionic acid herbicides.

They selectively kill plants by inhibiting a key enzyme.

But their activity is totally dependent on having that optically pure S2 -chloropropionic acid intermediate.

And the old chemical ways of making this were, I assume, messy and complicated.

Very.

The old route involved fermentation to get the wrong mirror image, the arylactic acid, and then this multi -step chemical conversion.

It was just not efficient at all.

But the current biotransformation is much more elegant.

It starts with a cheap commodity chemical.

Right.

It starts at the racemic 2 -chloropropionic acid.

And the key technology is an enzyme that does enantioselective dehalogenation.

It can clip off that chlorine atom.

And the microbe they got this enzyme from was found in a very logical place.

You could say that.

Scientists screened the environment and found a bacterium in the soil right next to a chemical factory that was using this very chemical.

So the bug had naturally evolved to break it down.

But it wasn't quite good enough for industry yet.

Not quite.

So they used mutagenesis to isolate a crucial mutant.

They found a strain whose enzyme was basically inactive on the desired S -isomer, but it was great at converting the undesired R -isomer into lactic acid.

Ah, so it acts like a molecular filter.

Yeah.

You put the 50 -50 mix in.

The enzyme specifically finds and destroys the half you don't want.

And you're left with a tank of the pure desired S2 -chloropropionic acid, which you can then just easily extract.

It's a brilliant example of asymmetric catalysis.

And what's really striking in all these examples is the common theme.

They're often using whole microbial cells, not purified enzymes, to get the job done effectively.

That brings up a really fundamental question.

Where do all these amazing super specialized enzymes even come from?

And the answer, of course, is just the mind -boggling scale of microbial diversity on our planet.

It's a vast and still largely untapped resource.

I mean, microbes, bacteria, archaea, fungi.

They've colonized pretty much every single ecological noosh on Earth.

Their enzymes are the product of billions of years of evolution, perfectly adapted to function under incredibly specific conditions.

So if an industrial chemist needs an enzyme that can handle boiling water or super high salt concentrations, they know exactly where to start looking.

Exactly.

We call those organisms extremophiles.

They thrive in environments that we would consider totally hostile to life.

We classify them based on what they love.

Hyperthermophiles love extreme heat, sacrophiles love the cold, halophiles love salt, and so on.

The enzymes from these organisms are unbelievably robust.

And the most famous example of an extremophile enzyme, the one that completely changed modern biology, has to be tac polymerase.

That is the absolute poster child.

Tac DNA polymerase was isolated from a bacterium called Thermus aquaticus, which was discovered living happily in a hot spring in Yellowstone National Park.

Its key feature is thermostability.

It has a half -life of 1 .6 hours, even at 95 degrees Celsius.

And that ability to survive those repeated high temperature cycles is what made the polymerase chain reaction, PCR,

possible to automate.

It changed everything.

Medicine, forensics, all of molecular biology.

All from a bug in hot water.

Precisely.

And the search for even better versions never stops.

But the comparison that really matters for high fidelity work, like gene cloning, is the error rate.

Right.

If you're making millions of copies of a gene, you need it to be accurate.

And tac polymerase, it lacks a proofreading mechanism.

It has a relatively high error rate.

But then came food DNA polymerase from another hyperthermophile, pyrococcus furiosus.

And it does have that proofreading ability, which drops the error rate dramatically.

It was a huge leap forward in quality.

So nature provides this amazing variety.

But traditionally, you had to find the organism and then figure out how to grow it in the lab, which is something most microbes just won't do.

But now we have a huge shortcut.

Screening environmental DNA or eDNA.

This has been the real game changer.

It's a culture independent method that has just unlocked all this potential.

You can take a sample of soil or ocean sediment or volcanic ash, and you can isolate all the DNA from the millions of organisms in there that you can't grow.

So you don't grow the microbe, you just steal its genetic blueprints.

In essence, yes.

You clone those DNA fragments into a host you can grow, like E.

coli, and then you just screen the resulting library for the enzyme function you're looking for.

It accelerates discovery exponentially.

We now have the tools to get almost any enzyme from the living world and produce it on a large scale.

Okay, so step one is finding the best available natural enzyme.

But as you said, an enzyme that evolved for a hot spring probably isn't perfectly suited for a giant industrial reactor.

So step two, which is almost always necessary, is optimization.

That's right.

It's actually rare for an industrial process to use a native microbial enzyme without any modifications.

The industrial environment is just too different, and trying to rationally predict which amino acid to change to get the result you want is incredibly difficult.

We just don't know all the rules of protein folding.

So instead, we mimic natural selection, but on hyperspeed, a process called directed evolution.

Exactly.

And a key technique here is DNA shuffling.

This is what you use when you have a family of related enzymes, but you don't have the detailed 3D structure you'd need to make surgical changes.

So how does DNA shuffling work?

It sounds like you're mixing and matching genes.

That's a great way to put it.

You start with a pool of similar genes, say from five different bacterial species.

You use an enzyme to randomly chop all those genes into little fragments.

So you have a big pile of DNA confetti from all five genes.

A big jumbled pile.

Then you heat it up to separate the DNA strands, and as it cools, the homologous fragments from different parent genes hybridize together.

They form these overlapping mismatched sequences.

Then you use PCR without any primers to reassemble them into full -length chimeric genes.

So you're creating millions of new hybrid enzymes, combining the best bits and pieces from all the original ones.

You are.

Then you clone those new genes and screen the whole library to find the ones with the improved properties you're looking for.

The best ones get pooled together for another round of shuffling.

You just repeat until the enzyme is perfect.

And the example of developing a glyphosate and acetyltransferase, or GATE enzyme for herbicide tolerance, really shows how powerful this is.

It does.

Glyphosate is the active ingredient in Roundup.

To make crops resistant, you need an enzyme to neutralize it.

Scientists found a GAT enzyme in a bacterium, but it was just way too weak for agricultural use.

It needed a huge performance boost.

A massive one.

So they took that weak gene and they put it through 11 iterations of DNA shuffling, mixing in diversity from four other related enzymes.

And the result after 11 rounds.

The final evolved enzyme showed an improvement in its overall efficiency of about 10 ,000 -fold over the original parent enzyme.

10 ,000 -fold.

Let's pause on that.

You're talking about the metric, Texanpreter.

For the listener, is that basically just the ultimate efficiency score for an enzyme?

That is the perfect way to describe it.

It's a measure of how fast and how effectively the enzyme works.

And getting a 10 ,000 -fold improvement meant this new enzyme was finally strong enough to give plants high tolerance to the herbicide.

It was a huge success for directed evolution.

Okay, so DNA shuffling mixes big chunks.

What if you have a good idea of which specific spot on the enzyme you want to change, but you want to try every possible option at that one spot?

For that, you use a technique called gene site saturation mutagenesis, or GSM.

This is a very systematic approach.

At one specific location, one codon, you systematically replace the existing amino acid with all 19 other possibilities.

But the math on that gets crazy fast.

If you target more than one site, the number of possible mutants just explodes.

It becomes astronomical.

Even just two substitutions can generate 15 million possible variants.

Three is over 50 billion.

So this absolutely requires high throughput screening.

You have to be able to test thousands of variants every single day.

And the optimization of a nitrolase for a lipid or precursor is a great example of GSM in action.

It is.

Researchers needed an enzyme to make an intermediate for the statin lipid.

They screened hundreds of EDNA libraries and found a nitrolase that worked, but only at low concentrations.

What happened when they tried to scale it up to industrial levels?

At high concentrations, its enantioselectivity just tanked.

It fell to an unacceptable 87 .6 % E.

So they used GSM to try and fix this problem.

And how did they screen all those millions of mutants so quickly?

This was really ingenious.

They developed a high throughput mass spectrometry assay.

They used a special labeled substrate.

And based on whether the enzyme removed the label or not, they could tell in an instant which mirror image it preferred.

It let them screen hundreds of samples an hour.

And the result of all that work?

They found a single amino acid change, all 90 He's, that completely fixed the problem.

The reaction time dropped from 24 hours to just 15 hours.

And the purity at high concentration shot up to 98 .1 % E.

It was a perfect industrial solution.

A third approach is error -prone mutagenesis.

How is that different?

Error -prone PCR, or EPCR, is a bit more of a shotgun approach.

You just use PCR conditions that intentionally introduce random mistakes all over the gene.

It's often used as a first step to generate some broad diversity before you do more targeted shuffling.

And we see this in the optimization of lipase from Pseudomonas aeruginosa.

Right.

The wild -type lipase was terrible.

It had an E value of 1 .1, way below the industrial target of 20.

They used multiple rounds of EPCR in screening, and they slowly climbed the ladder.

Interestingly, a lot of the early beneficial mutations were far away from the active site.

So how did they get all the way up to an E value over 20?

The big breakthrough came when they combined the two techniques.

They ran EPCR at a high mutation rate and then shuffled the resulting genes.

That created a mutant with an E value greater than 51 and 100 times more activity.

And what was the mechanism behind that huge improvement?

The modeling showed it was the cooperative effect of two distant mutations.

They weren't directly touching the substrate, but together they subtly reshaped the whole protein, and that indirectly created a brand new chiral pocket.

It's a perfect example of an outcome you could never have rationally designed.

Which brings us to the alternative approach,

rational methods of protein engineering.

This is for when you do have all the structural information.

Exactly.

When you have a high -resolution 3D crystal structure of your enzyme, and you know its mechanism inside and out, then you can use site -directed mutagenesis to make very precise surgical changes.

And the classic example here is the DER enzyme, which is essential for making statin precursors like those for Lipidar.

Right.

The DER enzyme does a key carbon -carbon bond forming reaction.

And crucially, scientists had solved its crystal structure at incredibly high resolution.

They had a perfect 3D blueprint of its active site.

And what was the engineering goal for the DER enzyme?

The wild type enzyme evolved to work with phosphorylated sugars.

It had a strong preference for them.

But for industrial synthesis, you want to use cheaper, unphosphorylated building blocks.

So the goal was to change its preference.

So they looked at the blueprint, specifically at the part of the enzyme that binds to the phosphate group.

Exactly.

The structural analysis showed that one amino acid, serine -238, made a direct hydrogen bond to the phosphate.

So the rational strategy was to mutate that serine to an aspartate.

This would introduce a negative charge and create an electrostatic repulsion with the negatively charged phosphate.

And did the rational design work as planned?

It worked beautifully.

The affinity for the natural phosphorylated substrate dropped 100 -fold, just as they predicted.

But the real win was that the catalytic rate for the unphosphorylated substrate, the one they wanted to use, was enhanced 2 .5 -fold.

It successfully shifted its preference.

Were there any unexpected benefits from that one precise change?

There was a great one.

The mutant enzyme gained the ability to work on even more novel, unnatural substrates.

It could now catalyze a reaction using three -azidopropanaldehyde, which the wild -type enzyme couldn't touch.

This opened up a whole new synthetic route for another lipitor intermediate.

Okay, we've covered the fundamentals, the history, the cutting -edge engineering.

Let's zoom out now to the colossal scale.

Because biocatalysis isn't just for fancy, high -value drugs, it's used to make massive quantities of commodity chemicals and food products all over the world.

Right, these large -scale processes are just text -butted examples of green chemistry.

They're simple, efficient, and have minimal waste.

And the highest -volume product that depends on biocatalysis is high -fructose corn syrup, or HFCS.

We're talking over a million tons produced annually.

And making HFCS is a multi -step process that starts with starch and needs three different enzymatic steps.

Can you walk us through that workflow?

Sure.

Step one is liquefaction.

This is where you convert starch into smaller chains called maltodextrins.

And this has to be done at extremely high temperatures, up to 107 degrees Celsius.

So you need a very special enzyme for that.

You need a hyperthermophilic one.

They use an alpha amylase from Bacillus licheniformis.

It's incredibly heat -stable.

Okay, so after liquefaction, you have these smaller chains.

Step two is turning them into pure glucose.

That's sacrifice.

And for this, they use two enzymes working together.

A glucoamylase from Aspergillus niger that splits the main chains and a polylinease from a Bacillus species that's needed to efficiently split the branch points in the starch.

And then the final critical step is turning that glucose into fructose, which is much, much sweeter.

That's the isomerization step.

It's catalyzed by an enzyme called xylose isomerase, which in this context is often just called glucose isomerase.

And it's the key step because fructose is nearly twice as sweet as table sugar, which makes it the go -to sweetener for the soft drink industry.

But getting this process to work on an industrial scale was a huge challenge at first, wasn't it?

A massive challenge.

The early process was totally uneconomical.

The enzyme had low affinity for glucose.

It was expensive to produce.

And worst of all, it required using arsenate in a food -grade process, which was a non -starter.

So how did they solve all those problems to get to the scale we have today?

The big breakthrough was switching to enzymes from streptomyces species.

Their isomerases didn't need arsenate.

And even better, some of them also produced another enzyme that allowed them to use cheap xylene from wood or straw to induce production, which cut the cost dramatically.

And the physical setup also changed from batch processing to continuous flow.

Yes.

Modern plants use these huge continuous flow reactors that are packed with immobilized enzyme.

And the efficiency is just astounding.

One kilogram of this immobilized enzyme can produce over 18 metric tons of fructose syrup.

It's a testament to optimizing the entire system.

Truly massive scale.

Okay, let's move to another key food application.

The transestrification of fats and oils to make things like cocoa butter substitutes.

This relies on a class of enzymes called lipases.

They are incredibly versatile.

They can break fats down, build them up, or swap fatty acid chains around.

The key is their positional specificity.

Some are very specific and only attack the outer positions of a triglyceride, while others are nonspecific.

And the goal here is to make high value cocoa butter substitutes.

Exactly.

Cocoa butter has a very specific composition that gives it that unique sharp melting point that you want in good chocolate.

And we can synthesize the main component of it by taking cheap palm oil and using a 1 euro 3 regio specific lipase to swap out the fatty acids with stearic acid.

And this process really highlights two key features of large scale biocatalysis that might surprise people.

It does.

First, it's done in a two -phase system.

The oily reactants are in an organic phase and the enzyme is in a tiny bit of water.

And second, and this is highly unusual, they're using a hydrolytic enzyme one that normally breaks bonds to do the exact opposite.

They're using it to synthesize bonds on a scale of over 10 ,000 tons a year.

Beyond food, lipases are even being used to make specialty polymers now.

This is a really interesting one for material science.

Making linear polyesters with a perfectly regular structure.

Traditional chemical synthesis often gives you low quality irregular polymers.

And the enzyme catalyzed route solves that problem.

It does.

They use an immobilized lipase from Canada, Antarctica to polymerize a dipic acid and butane one -olar four -dial and they do it completely in the absence of water.

The reaction happens in a precise four -step cycle inside the enzyme, which guarantees a perfectly regular structure.

And the result is a high molecular weight, high quality polymer that's perfect for things like coatings and adhesives.

Exactly.

It completely avoids the shortcomings of the chemical synthesis.

Okay, let's wrap up this industrial section with the production of acrylamide, a truly massive commodity chemical.

Yes, acrylamide production is over 200 ,000 tons per year.

It's one of the largest bio catalytic processes there is.

And the comparison to the old chemical route is just night and day.

Chemical synthesis uses copper salts at high temperature, you get a 70 -80 % yield and a bunch of toxic byproducts.

What makes the enzymatic process such a huge win for green chemistry?

The biotransformation uses immobilized whole cells of rotococcus rotocris.

The process runs in a bioreactor at just zero to five degrees Celsius.

And the yield is an incredible 99 .99 % with basically zero byproducts.

That is essentially a perfect conversion.

So it's cleaner, safer, and much more efficient.

And the energy savings are immense.

It uses far less steam and electricity than the high chemical process.

It's just a spectacular example of industrial sustainability and the clear competitive advantage of biocatalysis.

So to briefly recap our deep dive here, biocatalysis is really about using these highly specific microbial enzymes to do precise chemical transformations.

Its main advantages are that incredible stereospecificity, the efficiency, and the ability to work under very mild green conditions.

We saw the huge historical impact with Corzone, where one microbial step cut the synthesis from 31 steps to 11 and dropped the price 400 -fold.

We also looked at modern asymmetric catalysis, making these essential pure chiral building blocks for new drugs and agrochemicals, often using whole microbial cells.

And this whole field is being driven forward by relentless discovery, tapping into the diversity of extremophiles and these massive environmental DNA libraries.

And then crucially, taking those enzymes and rapidly optimizing them through directed evolution like DNA shuffling or by precise rational design when you have the 3D structure.

And the result is these huge industrial applications, everything from high fructose corn syrup and cocoa butter substitutes to the super high purity production of commodity chemicals like acrylamide.

Biocatalysis is not a niche thing anymore.

It is a fundamental part of global chemical manufacturing.

It really proves that sometimes the smallest organism is the best engineer.

So what does this all really mean for the future of chemistry?

What's the final thought for our listeners that you want?

Well, it raises a really important question that chemists are grappling with right now.

If the planet's microbial DNA represents this effectively infinite library of different enzyme

catalysts, and if our ability to screen those genes and then engineer those enzymes keeps improving at this exponential rate, what complex molecule that we currently consider impossible to synthesize will become a standard low cost product in the next decade?

The idea that the microscopic world holds the key to the macroscopic future of industrial synthesis.

That's the big idea.

A compelling final thought indeed.

Thank you for joining us on this deep dive into the revolutionary microbial magic in organic chemistry.

Thank you.

We hope you found these insights valuable.